Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia
Zanwar, Saurabh , Abeykoon, Jithma P. , Durot, Éric , King, Rebecca L. , Burbano, Gabriela E. Perez, Kumar, Shaji , Gertz, Morie A. , Quinquenel, Anne , Gonsalves, Wilson I. , Cornillet‐Lefèbvre, Pascale , He, Rong , Warsame, Rahma , Novak, Anne J. , Greipp, Patricia T. , Inwards, David J. , Micallef, Ivana N. , Muchtar, Eli , Kourelis, Taxiarchis , Lacy, Martha Q. , Dingli, David , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Johnston, Patrick B. , Thanarajasingam, Gita , Lin, Yi , Kyle, Robert A. , Ansell, Stephen M. , Kapoor, Prashant , Perez Burbano, Gabriela E, Gonsalves, Wilson , Warsame, Rahma , Inwards, David, Micallef, Ivana, Kourelis, Taxiarchis , Dispenzieri, Angela , Witzig, T.E. , Villasboas, Jose, Leung, Nelson , Rajkumar, S Vincent , Ansell, Stephen M , Kapoor, Prashant , Gertz, Morie A , Muchtar, E , Dingli, David , Greipp, Patricia T , Lin, Yi , Quinquenel, Anne , Burbano, Gabriela Perez , Delmer, Alain , Buadi, Francis K. , Habermann, Thomas M. , Go, Ronald S. , Dispenzieri, Angela , Bennani, N. Nora , Witzig, Thomas E. , Villasboas, José C. , Leung, Nelson , Rajkumar, S. Vincent , Le‐Rademacher, Jennifer

Mayo Clinic

American Journal of Hematology | December 9, 2019 | Volume: 95 | Issue: 3 | Pages: 274-281

10.1002/ajh.25697 | PMID 31814157 Get It

AbstractHistological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 L265P mutation on transformation. We examined risk factors and outcomes associated with transformation in WM, highlighting the role of MYD88 L265P mutation. Patients with WM seen at Mayo Clinic, Rochester, USA and University Hospital of Reims, France, between 01/01/1996 and December 31, 2017 were included; 50 (4.3%) of 1147 patients transformed to a high‐grade lymphoma, with median time‐to‐transformation of 4.5 (range 0‐21) years in the transformed cohort. The MYD88 L265P mutation status was known in 435/1147 (38%) patients (406 with non‐transformed WM and 29 patients in transformed cohort). On multivariate analysis, MYD88 WT status alone was an independent predictor of transformation (odds ratio, 7[95%CI: 2.1‐23]; P = .003). Additionally, the MYD88 WT status was independently associated with shorter time‐to‐transformation (HR 7.9 [95%CI: 2.3‐27; P = .001]), with a 5‐year transformation rate of 16% for MYD88 WT vs 2.8% with MYD88 L265P mutated patients. Patients with transformation demonstrated a significant increase in risk of death compared to patients who did not transform (HR 5.075; 95%CI: 3.8‐6.8; P < .001). In conclusion, the MYD88 WT status is an independent predictor of transformation and associated with a shorter time‐to‐transformation. Additionally, transformation conferred an inferior overall survival in patients with WM.
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, Timothy D. , Lin, Daniel W. , Aggarwal, Rahul , Chism, David D. , Cost, Nicholas G. , Derweesh, Ithaar , LaGrange, Chad A. , Levine, Ellis , Longo, Thomas A., Lowrance, Will, Rais‐Bahrami, Soroush , Sircar, Kanishka , Smith, David C. , Tzou, Katherine S., Vaena, Daniel A. , Vaughn, David J. , Yamzon, Jonathan , Johnson-Chilla, Alyse, Keller, Jennifer , Pluchino, Lenora A. , Tzou, Katherine, Emamekhoo, Hamid , Feldman, Darren Richard , Geynisman, Daniel M. , Hancock, Steven Lee , McGregor, Bradley A. , Monk, Paul , Picus, Joel , Pierorazio, Phillip , Saylor, Philip J. , Yamoah, Kosj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 5, 2019 | Volume: 17 | Issue: 12 | Pages: 1529-1554

10.6004/jnccn.2019.0058 | PMID 31805523 Get It

Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nerve-sparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with >50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.
AAPM medical physics practice guideline 7.a.: Supervision of medical physicist assistants
Seibert, J. Anthony , Blatnica, A, Clements, Jessica B., Halvorsen, Per H. , Herman, Michael , Johnson, Jennifer L. , Schueler, Beth A. , Martin, Melissa , Palta, Jatinder , Pfeiffer, D , Pizzutiello, R, Prisciandaro, Joann I. , Sherouse, George W., Herman, Michael G.

Mayo Clinic

Journal of Applied Clinical Medical Physics | December 4, 2019 | Volume: 21 | Issue: 7 | Pages: 11-15

10.1002/acm2.12774 | PMID 31800151 Get It

AbstractThe American Association of Physicists in Medicine (AAPM) is a nonprofit professional society whose primary purposes are to advance the science, education and professional practice of medical physics. The AAPM has more than 8,000 members and is the principal organization of medical physicists in the United States.The AAPM will periodically define new practice guidelines for medical physics practice to help advance the science of medical physics and to improve the quality of service to patients throughout the United States. Existing medical physics practice guidelines will be reviewed for the purpose of revision or renewal, as appropriate, on their fifth anniversary or sooner.Each medical physics practice guideline represents a policy statement by the AAPM, has undergone a thorough consensus process in which it has been subjected to extensive review, and requires the approval of the Professional Council. The medical physics practice guidelines recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guidelines and technical standards by those entities not providing these services is not authorized.The following terms are used in the AAPM practice guidelines: Must and Must Not: Used to indicate that adherence to the recommendation is considered necessary to conform to this practice guideline. Should and Should Not: Used to indicate a prudent practice to which exceptions may occasionally be made in appropriate circumstances. Approved by AAPM’s Executive Committee May 28, 2019
Association of Dietary Patterns in Midlife and Cognitive Function in Later Life in US Adults Without Dementia
Dearborn, Jennifer L. , Wu, Aozhou , Steffen, Lyn M. , Anderson, Cheryl A.M. , Hu, Emily A. , Knopman, David S. , Mosley, Thomas H. , Gottesman, Rebecca F.

Mayo Clinic

JAMA Network Open | December 4, 2019 | Volume: 2 | Issue: 12 | Pages: e1916641

10.1001/jamanetworkopen.2019.16641 | PMID 31800068 Get It

Abnormal Visual Contrast Acuity in Parkinson's Disease
Lin, Tanya, Rigby, Heather, Adler, Jennifer S. , Hentz, Joseph G. , Balcer, Laura J. , Galetta, Steven , Devick, Steve , Cronin, Richard, Adler, Charles H.

Mayo Clinic

Journal of Parkinson’s Disease | December 3, 2019 | Volume: 5 | Issue: 1 | Pages: 125-130

10.3233/jpd-140470 | PMID 25425583 Get It

Background: Low-contrast vision is thought to be reduced in Parkinson's disease (PD). This may have a direct impact on quality of life such as driving, using tools, finding objects, and mobility in low-light condition. Low-contrast letter acuity testing has been successful in assessing low-contrast vision in multiple sclerosis. We report the use of a new iPad application to measure low-contrast acuity in patients with PD. Objective: To evaluate low- and high-contrast letter acuity in PD patients and controls using a variable contrast acuity eye chart developed for the Apple iPad. Methods: Thirty-two PD and 71 control subjects were studied. Subjects viewed the Variable Contrast Acuity Chart on an iPad with both eyes open at two distances (40 cm and 2 m) and at high contrast (black and white visual acuity) and 2.5% low contrast. Acuity scores for the two groups were compared. Results: PD patients had significantly lower scores (indicating worse vision) for 2.5% low contrast at both distances and for high contrast at 2 m (p < 0.003) compared to controls. No significant difference was found between the two groups for high contrast at 40 cm (p = 0.12). Conclusions: Parkinson's disease patients have reduced low and high contrast acuity compared to controls. An iPad app, as used in this study, could serve as a quick screening tool to complement more formal testing of patients with PD and other neurologic disorders.
Triptan and ergotamine overdoses in the United States
Robblee, Jennifer , Butterfield, Richard , Kang, A. Min , Robblee, Jennifer V , Butterfield, Richard J, Smith, Jonathan H.

Mayo Clinic

Neurology | December 3, 2019 | Volume: 94 | Issue: 14 | Pages: No page available

10.1212/wnl.0000000000008685 | PMID 31792093 Get It

A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience
Rieck, Thomas , Lee, Jennifer R., Ferguson, Jennifer A., Peterson, Laura A., Lillie, Charlene M Martin, Clark, Matthew M. , Bauer, Brent A. , Rieck, Thomas M , Martin Lillie, Charlene M, Limburg, Paul J.

Mayo Clinic

Global Advances in Health and Medicine | November 29, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119892597 | PMID 31827983 Get It

Objectives The aim of this study was to compare the stress reduction effects of spending 25 minutes reclining in a SolTec™ Lounge between 2 intervention groups. Group 1 experienced the Lounge with multilayered music on an external speaker, while group 2 experienced the Lounge with multilayered music and synchronous vibration and magnetic stimulation from within the chair. Subjects In total, 110 participants with a self-reported stress level of 4 or higher on a 0- to 10-point scale were recruited from the local community including employees. Participants were randomized into receiving 1 of the 2 interventions. There were no significant differences between the group’s average stress levels prior to the interventions. Interventions Both groups received a 25-minute session in a dimly lit, quiet area on the Lounge with multilayered music. The second group also received vibration and magnetic stimulation that were synchronized with the music. Design Current stress level as well as ratings or feelings of anxiety, tenseness, energy, focus, happiness, relaxation, nervousness, creativeness, and being rested were recorded before and after the session. Results Both groups of participants reported equivalent decreased feelings of stress after using the Lounge. Participants receiving the synchronous multilayered music, vibration, and magnetic stimulation did report significantly reduced feelings of tenseness, feeling more relaxed, and feeling more creative when compared with the group that received music only. Conclusion Spending 25 minutes in the SolTec™ Lounge with multilayered music is an effective way to reduce self-reported stress in individuals who self-report having a high stress level. If confirmed by future studies, including synchronous vibration and magnetic stimulation with the multilayered music might be an effective stress reduction strategy.
Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline
Wallach, Asya I. , Waltz, Michael , Casper, T. Charles , Aaen, Gregory , Belman, Anita , Chitnis, Tanuja , Gorman, Mark , Graves, Jennifer , Harris, Yolanda, Lotze, Timothy , Mar, Soe , Moodley, Manikum , Ness, Jayne , Rodriguez, Moses , Rose, John , Schreiner, Teri , Tillema, Jan‐Mendelt , Charvet, Leigh , Krupp, Lauren , Chitnis, Tanuja , Graves, Jennifer , Krupp, Lauren , Rodriguez, Moses , Charvet, Leigh E , Benson, Leslie, Rensel, Mary R. , Schreiner, Teri , Waubant, Emmanuelle L. , Weinstock‐Guttman, Bianca

Mayo Clinic

Multiple Sclerosis Journal | November 28, 2019 | Volume: 26 | Issue: 14 | Pages: 1938-1947

10.1177/1352458519891984 | PMID 31775571 Get It

Background: Cognitive impairment occurs in approximately one-third of pediatric-onset multiple sclerosis (POMS) patients. The Symbol Digit Modalities Test (SDMT), a widely used cognitive screen in adults, has yet to be incorporated early into the standard care of POMS. Objective: To screen for cognitive impairment early in the course of POMS and analyze predictive factors. Methods: Of the 955 POMS or clinically isolated syndrome (CIS) patients prospectively assessed from March 2014 to July 2018, 500 POMS and 116 CIS patients met inclusion criteria (disease onset before the age of 18, one or more SDMTs, and 8 years or older at the time of testing). Those with relapse were analyzed separately from those who were relapse-free. Results: At initial assessment, the mean (interquartile range (IQR)) age at symptom onset was 13.5 years (12.0, 15.9) and the mean (±SD) disease duration was 3.0 ± 2.9 years. Impaired processing speed occurred in 23.4% of POMS and in 16.4% of CIS. On serial testing ( n = 383, mean follow-up: 1.8 years), 14.1% had clinically meaningful decline predicted by older age of multiple sclerosis (MS) onset and male gender. Disease relapse or steroid use led to transient worsening on the SDMT. Conclusion: Early in the disease, some POMS and CIS patients are at risk for cognitive impairment and subsequent decline.
Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome
Ding, Katharina J., Cammann, Victoria L. , Szawan, Konrad A. , Stähli, Barbara E. , Wischnewsky, Manfred , Vece, Davide Di , Citro, Rodolfo , Sarcon, Annahita, Knorr, Maike, Heiner, Susanne, Gili, Sebastiano , Napp, L. Christian , Franke, Jennifer , Burgdorf, Christof , Köenig, Wolfgang , Kherad, Behrouz , Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Arroja, José David , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Fischer, Thomas, Vasankari, Tuija , Paolini, Carla , Bilato, Claudio , Carrilho‐Ferreira, Pedro , Opolski, Grzegorz , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , El‐Battrawy, Ibrahim , Akın, İbrahim , Gilyarova, Ekaterina, Gilyarov, Mikhail , Kozel, Martin , Widimský, Petr , Winchester, David E. , Ukena, Christian , Prasad, Abhiram , Rihal, Charanjit S. , Pinto, Fausto J. , Borggrefe, Martin, Rottbauer, Wolfgang , Katus, Hugo A. , Tschöpe, Carsten , Pieske, Burkert , Böhm, Michael , Felix, Stephan B. , Münzel, Thomas , Lüscher, Thomas F. , Ghadri, Jelena R. , Bossone, Eduardo , Templin, Christian , Gilyarov, Mikhail , Bossone, Eduardo , Citro, Rodolfo , El-Battrawy, Ibrahim , Prasad, Abhiram , Tschöpe, Carsten , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Kobza, Richard , Gilyarov, Mikhail , Ukena, Christian , Bilato, Claudio , Jaguszewski, Miłosz , Seifert, Burkhardt , D’Ascenzo, Fabrizio , Neuhaus, Michael, Noutsias, Michel , Airaksinen, Juhani , Kaiser, Christoph A. , Dichtl, Wolfgang , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , Toušek, Petr , Gałuszka, Jan , Horowitz, John D. , Mario, Carlo Di , Rihal, Charanjit S. , Crea, Filippo , Braun-Dullaeus, Ruediger Christian , Bauersachs, Johann , Hasenfuß, Gerd , Thiele, Hölger , Schunkert, Heribert , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | November 26, 2019 | Volume: 40 | Issue: 1 | Pages: 279-287

10.1161/atvbaha.119.313491 | PMID 31766870 Get It

Objective: Takotsubo syndrome (TTS) is characterized by acute left ventricular dysfunction, which can contribute to intraventricular thrombus and embolism. Still, prevalence and clinical impact of thrombus formation and embolic events on outcome of TTS patients remain unclear. This study aimed to investigate clinical features and outcomes of patients with and without intraventricular thrombus or embolism. Additionally, factors associated with thrombus formation or embolism, as well as predictors for mortality, were identified. Approach and Results: TTS patients enrolled in the International Takotsubo Registry at 28 centers in Australia, Europe, and the United States were dichotomized according to the occurrence/absence of intraventricular thrombus or embolism. Patients with intraventricular thrombus or embolism were defined as the ThrombEmb group. Of 1676 TTS patients, 56 (3.3%) patients developed intraventricular thrombus and/or embolism following TTS diagnosis (median time interval, 2.0 days [range, 0–38 days]). Patients in the ThrombEmb group had a different clinical profile including lower left ventricular ejection fraction, higher prevalence of the apical type, elevated levels of troponin and inflammatory markers, and higher prevalence of vascular disease. In a Firth bias-reduced penalized-likelihood logistic regression model apical type, left ventricular ejection fraction ≤30%, previous vascular disease, and a white blood cell count on admission >10×10 3 cells/μL emerged as independent predictors for thrombus formation or embolism. Conclusions: Intraventricular thrombus or embolism occur in 3.3% of patients in the acute phase of TTS. A simple risk score including clinical parameters associated with intraventricular thrombus formation or embolism identifies patients at increased risk. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01947621.